Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.